Notably, the silencing of MYC and MYCN oncogenes led to a down-regulation of PD-L1 expression in NB cells, both in vitro and in vivo, thus suggesting that the pharmacological inhibition of this axis may be used as a therapeutic strategy in high-risk NB patients [109]. This evidence concerns the gene MYCN and neuroblastoma.